REDHILL BIOPHARMA IMAGE: REDHILL’S OPAGANIB MECHANISM UNAFFECTED BY OMICRON MUTATIONS CREDIT: REDHILL BIOPHARMA TEL AVIV, Israel and RALEIGH, NC, December 6, 2021, RedHill Biopharma Ltd.(Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that because opaganib’s proposed mechanism of action is not impacted by spike protein mutations, opaganib is expected to be...